Suppliers versus systems: the margin tug-of-war

Follow the implant

Start with that $30,000 hip.

A hospital's single largest non-labor cost category is often physician preference items (PPIs): implants, pacemakers, and surgical devices that a specific doctor insists on using. Orthopedic and cardiac devices dominate this bucket.

Here is the leverage problem. The surgeon picks the brand. The hospital pays the bill. The two decisions are decoupled, which is exactly how device makers like it. Sales reps build relationships directly with surgeons, sometimes standing in the operating room during procedures. The hospital procurement team is negotiating a price for a product it cannot actually swap out without a physician revolt.

That is why device gross margins are famously high. Publicly, large orthopedic makers routinely report gross margins in the 65 to 75 percent range (as reported in their annual filings; treat exact figures as company and year specific). The device is not expensive to make. It is expensive to *sell into a system that cannot say no.*

How systems claw it back: physician-preference discipline

The counter-lever is unglamorous: price transparency plus physician engagement.

Leading systems now show surgeons the actual cost of the implants they choose, side by side, and tie a share of savings to physician compensation or department budgets. When a surgeon sees that Implant A and Implant B have equivalent clinical outcomes but a $4,000 price difference, behavior shifts.

Systems also use capitated or "construct" pricing: negotiating a single bundled price per procedure regardless of which components the surgeon selects. This removes the device maker's ability to upsell premium parts inside one operation.

The tug-of-war here is cultural as much as financial. The supplier owns the relationship with the doctor. The system has to win that relationship back with data.

Follow the drug

Now trace a blockbuster drug, say an infused biologic for cancer or autoimmune disease that costs several thousand dollars per dose.

The pharmaceutical maker sets a list price. But almost nobody pays list. Between the manufacturer and the hospital sit rebates (paid to pharmacy benefit managers and payers) and distributor margins. The gross-to-net gap in US pharma is enormous: list prices and actual received prices can differ by tens of percent.

For hospitals that administer drugs directly (chemotherapy, infusions), the drug is both a clinical tool and a revenue line. Medicare traditionally reimbursed these under a formula of ASP (Average Sales Price) plus a percentage markup. That markup is the hospital's spread. Suppliers know it, and price accordingly.

How systems claw it back: 340B

The single most powerful drug-margin lever US hospitals hold is the 340B Drug Pricing Program.

Created by federal law in 1992 and run by HRSA, 340B requires drug manufacturers to sell outpatient drugs at deep discounts to eligible "safety-net" hospitals and clinics: those serving large low-income populations. The discount is often estimated in the range of 25 to 50 percent off, depending on the drug.

The mechanics that make it lucrative: a 340B hospital buys the drug cheap, administers it to a patient, and then bills the insurer or Medicare at the normal (non-discounted) rate. The spread between the discounted purchase and the full reimbursement stays with the hospital. It is intended to stretch scarce resources for vulnerable patients.

This is real money. 340B purchases have grown into a very large program (tens of billions of dollars in discounted drug purchases annually, per HRSA reporting; treat the exact figure as an estimate that grows year over year). Read the program basics directly from the source: HRSA's 340B overview.

The fight over 340B defines a current power struggle. Manufacturers argue the program has expanded far beyond its charitable intent and have moved to restrict discounts, especially for drugs dispensed through outside "contract pharmacies." Hospitals and their lobby fight to protect it. Expect litigation and CMS rule changes to continue through 2026.

🎬 [VIDEO: "How the 340B Drug Pricing Program Works" - https://www.youtube.com/results?search_query=340B+drug+pricing+program+explained - a short explainer on the discount mechanics and the ongoing manufacturer disputes]

The GPO in the middle

Where do GPOs fit? They aggregate the purchasing power of hundreds of hospitals to negotiate lower prices from suppliers, then charge suppliers administrative fees (typically capped by a safe harbor under federal anti-kickback rules at a small percentage of sales).

This creates an unusual dynamic: the GPO is paid by the *supplier* while claiming to serve the *hospital*. Critics argue this misaligns incentives, especially for commodity supplies. Defenders point to real savings on high-volume items like gloves, IV bags, and generic drugs.

GPOs are strong on commodities and weak on PPIs. They cannot easily negotiate down an implant that one surgeon demands by name. So the tug-of-war splits: GPOs win the commodity battle, but the device makers keep winning the preference-item battle.

Reading the balance of power

Step back and the pattern is clear.

Where suppliers hold power:

• Physician-preference devices, because the buyer and the decider are different people.
• Sole-source and patented drugs with no biosimilar competition.
• Any product where switching creates clinical risk or retraining cost.

Where systems hold power:

• Commodity supplies bought through GPOs.
• Drug categories with biosimilar competition (a biologic losing exclusivity can see prices fall sharply once rivals enter).
• 340B-eligible outpatient drugs, where the discount plus full reimbursement flips the margin toward the hospital.
• Any category where the system can standardize physician behavior with data.

Europe contrast (brief): In many European systems, national or regional bodies negotiate drug and device prices centrally, and single-payer purchasing suppresses the supplier margins that thrive in the fragmented US market. There is no 340B equivalent because the pricing power sits with the state, not individual hospitals. Device makers earn lower prices per unit in Europe than in the US, a difference well documented in health economics literature.

A simple worked example

A 340B hospital administers a biologic:

• Manufacturer list price per dose: $5,000 (illustrative)
• 340B discounted purchase price: $3,000 (assume a 40 percent discount, illustrative)
• Reimbursement received from payer: $5,100 (list plus small markup, illustrative)

Margin captured on this dose:

$5,100 (reimbursement) minus $3,000 (340B cost) = $2,100 per dose.

A non-340B hospital buying at $4,800 net and reimbursed $5,100 captures only $300. Same drug, same patient, radically different economics. That single lever is why 340B eligibility is worth fighting over.

Key takeaways

• The margin lives where decision and payment are separated. Physician-preference items like orthopedic implants stay expensive because the surgeon chooses and the hospital pays. Reconnecting those decisions with cost transparency is the system's main clawback.
• 340B is the hospital's heaviest drug-margin lever in the US. Buy discounted, bill at full rate, keep the spread. It is under sustained attack from manufacturers and shifting CMS rules.
• GPOs win commodities, not preference items. They aggregate volume for gloves and generics but cannot override a surgeon's brand demand.
• Supplier gross margins signal pricing power, not manufacturing cost. Device makers report 65 to 75 percent gross margins (company and year specific) because they sell into buyers who struggle to say no.
• Geography changes everything. Central price negotiation in much of Europe compresses the supplier margins that flourish in the fragmented US market.